ARCT Arcturus Therapeutics Holdings Inc.
USHealthcareAs of 2026-07-10 16:00
Why ARCT matters now
Arcturus Therapeutics Holdings Inc. (ARCT) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.97 with -2.65% on the session and $198.1M in market capitalization; recent performance reads 1-month +12.56% and YTD +22.84%.
The latest financial table shown here is Q1 2026, with revenue of $610.0K, net income of $-27.0M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.5%.
The latest indexable market news headline is "Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.50; recent insider activity includes Marantz Jing L. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.12
P/S
4.72
EV/EBITDA
-0.39
DCF Value
$-5.70
FCF Yield
-27.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-196.7%
Net Margin
-173.5%
ROE
-36.6%
ROA
-32.1%
ROIC
-41.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $610.0K | $-27.0M | $-0.95 |
| Q4 2025 | $3.1M | $-29.1M | $-1.05 |
| FY 2025 | $67.2M | $-65.8M | $-2.40 |
| Q3 2025 | $17.2M | $-13.4M | $-0.49 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.50
Target (Median)
$22.50
Target Range
$20.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.35
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.